Generate Biomedicines, Inc. (GENB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Based on dividend-adjusted daily data since Feb 27, 2026, GENB's average daily return is +0.22%, while the average monthly return is +0.46%. At this rate, an investment would double in approximately 12.6 years.

Historically, 50% of months were positive and 50% were negative. The best month was May 2026 with a return of +3.9%, while the worst month was Jun 2026 at -1.9%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 1 months.

On a daily basis, GENB closed higher 53% of trading days. The best single day was Jun 4, 2026 with a return of +13.9%, while the worst single day was May 18, 2026 at -18.7%.

Generate Biomedicines, Inc. has an annualized alpha of 16.18%, beta of 1.46, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since March 02, 2026.

• This stock participated in 45.40% of S&P 500 Index downside but only 23.25% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for Generate Biomedicines, Inc. (GENB) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Generate Biomedicines, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Generate Biomedicines, Inc. was 26.20%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Generate Biomedicines, Inc. drawdown is 20.65%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Generate Biomedicines, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Generate Biomedicines, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.